- Conditions
- Dry Eye Disease
- Interventions
- AG-80308
- Drug
- Lead sponsor
- Allgenesis Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Raynham, Massachusetts • Clinton, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lymphoma
- Interventions
- busulfan, cyclophosphamide, etoposide, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 15 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
- Interventions
- ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab
- Drug
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Fairfax, Virginia
- Conditions
- Gonococcal Infection
- Interventions
- Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 36 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Healthy Volunteers, Primary Sclerosing Cholangitis
- Interventions
- TAK-781, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pain
- Interventions
- VX-548, Midazolam, Digoxin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Solid Tumors
- Interventions
- DS-8201a (DP1), DS-8201a (DP2), DS-8201a (DP)
- Drug
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 8
- States / cities
- San Diego, California • Jacksonville, Florida • Louisville, Kentucky + 5 more
- Conditions
- Heart Failure
- Interventions
- LCZ696, valsartan, LCZ696 placebo, valsartan placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 38
- States / cities
- Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
- Conditions
- Pancreatic Cancer, Metastatic
- Interventions
- Gemcitabine, Erlotinib, OSI-906, Gemcitabine, Erlotinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Epilepsy
- Interventions
- Levetiracetam
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 4 Years to 16 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 9
- States / cities
- La Jolla, California • Boston, Massachusetts • Chesterfield, Missouri + 6 more
- Conditions
- PTCL, CTCL
- Interventions
- Pembrolizumab, Pralatrexate, Decitabine
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Charlottesville, Virginia
- Conditions
- Colorectal Carcinoma
- Interventions
- Cetuximab and Radiation Therapy, Surgery and Radiation Therapy
- Other · Procedure
- Lead sponsor
- American Scitech International
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Englishtown, New Jersey
- Conditions
- Focus of Study is on Healthy Lactating Women
- Interventions
- LYBALVI
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Chronic Hepatitis C
- Interventions
- VX-985 or matching placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Overland Park, Kansas • Baltimore, Maryland • Tacoma, Washington
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 25 more
- Conditions
- Alcoholic Hepatitis
- Interventions
- DUR-928 (Moderate AH), DUR-928 (Severe AH)
- Drug
- Lead sponsor
- Craig James McClain
- Other
- Eligibility
- 21 Years to 67 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Primary Biliary Cholangitis, PBC
- Interventions
- Volixibat, Placebo
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 44
- States / cities
- Coronado, California • Los Angeles, California • Sacramento, California + 38 more
- Conditions
- Patients With Advanced Solid Tumors
- Interventions
- Treatment with ICVB-1042 administered intravenously
- Drug
- Lead sponsor
- IconOVir Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- San Marcos, California • Detroit, Michigan • New York, New York + 7 more
- Conditions
- Stroke, Acute
- Interventions
- Placebo, Nerinetide
- Drug
- Lead sponsor
- NoNO Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Torrance, California • Englewood, Colorado + 14 more
- Conditions
- IPMN, IPMN, Pancreatic
- Interventions
- Sulindac 400 MG, Placebo
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Solid Tumors
- Interventions
- Cobimetinib, Pictilisib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- Healthy Volunteers
- Interventions
- ABBV-722
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: BG-T187, Other Therapeutic Agents
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Houston, Texas • Fairfax, Virginia + 1 more
- Conditions
- Malignancies, B-Cell Lymphoma
- Interventions
- Aroplatin
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas